TriangleAfatinib (NCT02491099)
Afatinib trial for HER2/Neu+ Uterine Serous Carcinoma (NCT02491099). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for women aged eighteen to one hundred with measurable persistent or recurrent uterine serous cancer. HER2 must score three-plus, or two-plus with gene amplification.
The idea: afatinib blocks growth signals through HER-family receptors. Patients take forty milligrams orally daily. Cycles last twenty-one days initially, then twenty-eight days after twelve weeks. Researchers assess six-month progression-free survival, tumor response, and safety. Prior trastuzumab is allowed; prior anthracyclines or irreversible HER-family inhibitors are excluded.
This phase 2 study plans 50 patients. Alessandro Santin leads at Yale, New Haven, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.